About Sana Biotechnology
Sana Biotechnology is a publicly listed company based in Seattle (United States) founded in 2018 by Michael Mee, Jacob Rubens, Geoffrey Von Maltzahn, Steve Harr, and Jack Milwid. Genetically engineered cell therapies are developed for multiple disorders. Sana Biotechnology has raised $821 million across 2 funding rounds from investors including Mayo Clinic, Flagship Pioneering and Baillie Gifford. The company has 253 employees. Sana Biotechnology has completed 1 acquisition, including Oscine Therapeutics. Its chief executive, as recorded, is Steve Harr. Its website sana.com draws about 29 thousand monthly visits. Sana Biotechnology offers products and services including Engineered Cell Therapies and Drug Candidates. Its focus areas include Life Sciences, Cell Therapy, Adoptive Cell Therapy and Diversified. Its legal entity is SANA BIOTECHNOLOGY, INC. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
Sana Biotechnology was founded in 2018 and is headquartered in Seattle, United States. Operations focus on the biotechnology sector, where genetically engineered cell therapies are created to address disorders such as Non-Hodgkin lymphoma, multiple myeloma, diabetes, and central nervous system conditions. Drug candidates like SC291, SC255, SC451, and SC379 are advanced through gene therapy and editing techniques to reprogram cells in the body or replace damaged tissues.
- Headquarters Seattle, United States
- Employees 253
- Founders Michael Mee, Jacob Rubens, Geoffrey Von Maltzahn, Steve Harr, Jack Milwid
- Stage Public
- SectorsHealthcare
- Website category Computers Electronics and Technology · Graphics Multimedia and Web Design
- Email••••••••
- Website sana.com
- Social LinkedIn X
- Legal Name Sana Biotechnology, Inc.
- Net Profit-$244.17 M (USD)8.47as on Dec 31, 2025
- EBITDA-$178.21 M (USD)30.38as on Dec 31, 2025
- Total Equity Funding$821M (USD)
in 2 rounds
- Latest Funding Round$25M (USD), Post-IPO
Aug 2026
- InvestorsMayo Clinic
& 18 more
- Employee Count253
- Investments & Acquisitions
Products & Services of Sana Biotechnology
Sana Biotechnology offers a comprehensive portfolio of products and services, including Engineered Cell Therapies and Drug Candidates.
Develops treatments by modifying cells to repair genes for diseases.
Advances therapies targeting cancer and autoimmune disorders through innovation.
Funding Insights of Sana Biotechnology
Sana Biotechnology has successfully raised a total of $821M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $821M
- Total Rounds 2
- Last Round Post-IPO — $25M
- First Round $821M
(Jun 2020)
- Investors Count 19
All 2 funding rounds of Sana Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | $25M | Post-IPO | – | – | |
| Jun 2020 | $821M | Series D | – | F-Prime Capital, Arch Venture Partners | – |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of Sana Biotechnology
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
19 investors in total: 19 institutional.
Investors in Sana Biotechnology
Sana Biotechnology has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Mayo Clinic, Flagship Pioneering and Baillie Gifford.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Investment management and philanthropic ventures linked to Bezos Expeditions. | bezosexpeditions.com | |||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital firm | omegafunds.com | Boston, United States | ||
Early stage life sciences sectors focused VC firm investing in the US | altitudelsv.com | Kirkland, United States | ||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
Venture capital fund investing in tech sectors | innovating.capital | New York, United States | ||
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom |
Investor details for Sana Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sana Biotechnology
76 people are tracked at Sana Biotechnology (36 in leadership, 9 in board & advisors, 31 in team); the tracked headcount is 253.
| Name | Role | Group |
|---|---|---|
Michael Mee | Co-Founder | Leadership |
Jacob Rubens | Co-Founder | Leadership |
Geoffrey Von Maltzahn | Co-Founder | Leadership |
Steve Harr | Co-Founder & CEO | Leadership |
Jack Milwid | Founder | Leadership |
Nate Hardy | CFO | Leadership |
Terry Fry | Head of T Cell Therapeutics | Leadership |
Alexandra Bowden | Executive Director, Sana Biotechnology | Leadership |
Ryan Zolyomi | Associate Director, Viral Vector Process Development | Leadership |
Snehal Patel | Head of Technical Operations | Leadership |
Sundeep Chandra | Pathologist - Executive Director | Leadership |
Carlos Villarreal | Head Of Site And Lab Ops, Bothell And EHS | Leadership |
Josh Hanigan | Director, IT Infrastructure | Leadership |
Jill Dierx | Senior Director Vector Production | Leadership |
Yi Ying | Director | Leadership |
Autumn Moore | Director, Environmental Health Safety | Leadership |
Albert Ruzo | Senior Director | Leadership |
Michael Londergan | Executive Director Finance | Leadership |
Sunny Patel | Vice President, Head Of R&d Program & Alliance Management | Leadership |
Xiaoyu Chen | Senior Director, Bioinformatics Development | Leadership |
56 more people are available in the full profile.
Complete people profiles for Sana Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sana Biotechnology
Sana Biotechnology is a publicly listed company on the NASDAQ with ticker symbol SANA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Feb 2021
- Listed onNASDAQ: SANA
- Listed entitySana Biotechnology, Inc.
- Exchange sectorHealth technology
- ISINUS7995661045
- Share price$2.41 (-8.02% on the day) · 2026-10-13
- Market capitalisation$721.5M
- EPS (diluted, trailing year)$-0.76
- Volume (last session)4,911,407
Financials of Sana Biotechnology
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$244.2M | -$178.2M | |
| 2024 | -$266.8M | -$256.0M | |
| 2023 | -$283.2M | -$294.9M | |
| 2022 | -$269.5M | -$241.3M | |
| 2021 | -$355.9M | -$228.7M |
Detailed financial statements for Sana Biotechnology
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sana Biotechnology
Sana Biotechnology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Oscine Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Stem cell-based therapeutics are developed for CNS diseases. | oscinetherapeutics.com | New York, United States | 2017 | Nov 2020 | •••• |
Complete acquisition details for Sana Biotechnology
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sana Biotechnology
6 dated milestones of Sana Biotechnology across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Sana Biotechnology is founded.
- Funding First funding round of $821.0M.
- Milestone Reaches Unicorn status.
- Acquisition Acquires Oscine Therapeutics.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $25.0M.
Competitors of Sana Biotechnology
Sana Biotechnology has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of Sana Biotechnology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sana Biotechnology
The website of Sana Biotechnology (sana.com) receives about 28.6K visits a month and ranks #675,230 among all websites worldwide, #6,699 in Graphics Multimedia and Web Design.
- Monthly visits28.6K
▼ 23.4% vs previous month
- Unique visitors18K
per month
- Global rank#675,230
among all websites
- Category rank#6,699
Computers Electronics and Technology · Graphics Multimedia and Web Design
- Bounce rate35%
- Pages per visit3.2
- Average visit42 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with Sana Biotechnology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
kapandcompany.com | kapandcompany.com | 100% | – | ||
redtusk.com | redtusk.com | 100% | – | ||
realcharactersinc.com | realcharactersinc.com | 100% | – | ||
spectrumdesigngroup.net | spectrumdesigngroup.net | 100% | – | ||
solodesign.net | solodesign.net | 100% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for Sana Biotechnology
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Sana Biotechnology (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sana Biotechnology
Complete news archive for Sana Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sana Biotechnology
Sana Biotechnology was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Sana Biotechnology is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Steve Harr is the CEO of Sana Biotechnology, as recorded in our data. They have also founded this company.
Sana Biotechnology is a funded company, having raised a total of $821M across 2 funding rounds to date. The company's 1st funding round was a Series D of $821M, raised on Jun 2020.
Sana Biotechnology has 253 employees.
Sana Biotechnology was founded in 2018 and is headquartered in Seattle, United States. Operations focus on the biotechnology sector, where genetically engineered cell therapies are created to address disorders such as Non-Hodgkin lymphoma, multiple myeloma, diabetes, and central nervous system conditions. Drug candidates like SC291, SC255, SC451, and SC379 are advanced through gene therapy and editing techniques to reprogram cells in the body or replace damaged tissues.
Sana Biotechnology offers Engineered Cell Therapies and Drug Candidates.
Yes, Sana Biotechnology is publicly traded on NASDAQ under the ticker symbol SANA.
Sana Biotechnology has made 1 acquisition, including Oscine Therapeutics.
Sana Biotechnology has 19 investors. Key investors include Mayo Clinic, Flagship Pioneering, Baillie Gifford, CPP Investments, and Arch Venture Partners.
Sana Biotechnology operates through Sana Biotechnology, Inc..